Brief: Compugen Says Co Will be Eligible to Receive $10 Mln Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial
19/12/2023 13:23
Dec 19 (Reuters) - AstraZeneca PLC AZN.L :
* COMPUGEN WILL BE ELIGIBLE TO RECEIVE $10 MILLION MILESTONE
PAYMENT UPON DOSING OF FIRST PATIENT IN ASTRAZENECA PHASE 3
RILVEGOSTOMIG TRIAL IN BILIARY TRACT CANCER
Source text for Eikon: ID:nPnbP7Wpna
Further company coverage: AZN.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025